MarketBeat is an American financial media company headquartered in Sioux Falls, South Dakota, founded in 2011 by Matthew Paulson as Analyst Ratings Network before rebranding in 2015. The company operates an online platform that delivers real-time financial data, market analysis, and news, aiming to empower individual investors with tools to make informed trading decisions.
Hemab Therapeutics (NASDAQ:COAG) Chief Executive Officer Benny Sorensen outlined the company’s development plans following its recent initial public offering during a fireside chat with Jefferies biotech analyst Maury Raycroft.
Sorensen said Hemab is pursuing a strategy to build “a multiple product
Zepp Health (NYSE:ZEPP) reported a stronger start to 2026, with management pointing to new Amazfit product launches, a higher-end product mix and expanding positioning in hybrid training as the main drivers of first-quarter growth.
On the company’s earnings call, Founder and Chief Executive Officer
CareDx (NASDAQ:CDNA) executives outlined the company’s strategy to focus on precision diagnostics, expand into minimal residual disease testing and improve profitability during a Goldman Sachs-hosted discussion.
Chief Executive Officer John Hanna said CareDx has reshaped its portfolio around areas
Bioventus (NASDAQ:BVS) executives outlined the company’s portfolio strategy, growth priorities and capital allocation plans during a Goldman Sachs event hosted by Jenny Rabinowitz, an analyst covering U.S. medtech and healthcare IT.
Mark Singleton, Bioventus’ senior vice president and chief financi
Vail Resorts (NYSE:MTN) said historically poor weather across the Western United States continued to weigh on fiscal third-quarter results, pressuring visitation and revenue at its mountain resorts while management emphasized that its advance commitment pass model and cost controls helped cushion th
Gloo (NASDAQ:GLOO) reported fiscal first-quarter revenue and adjusted EBITDA ahead of its own guidance and Wall Street consensus, as executives pointed to momentum from large strategic customers, recent acquisitions and growing demand for AI-enabled technology and marketing tools across faith-based
Mama's Creations (NASDAQ:MAMA) reported sharply higher first-quarter fiscal 2027 results, with management pointing to new retail placements, the Crown I acquisition and broader customer growth as the main drivers, even as gross margins were pressured by launch-related costs.
Chairman and CEO Adam L
Mission Produce (NASDAQ:AVO) said its fiscal second quarter was pressured by an unusually high-supply avocado market, particularly from Mexico, which drove prices to multi-year lows and compressed margins despite higher avocado volumes.
President and Chief Executive Officer John Pawlowski, who form
Motorcar Parts of America (NASDAQ:MPAA) reported stronger fiscal fourth-quarter and full-year results, with management pointing to sales momentum, new business commitments and improving profitability as key drivers heading into fiscal 2027.
Chairman, President and Chief Executive Officer Selwyn Jof
Amprius Technology is on track to set a new all-time high later this year after it reports Q2 results and guidance. Short interest suggests a squeeze is possible.
Broadcom, Palo Alto Networks, and Planet Labs each reported strong results and offer potential upside as investors position for the second half of 2025.
A weaker dollar means international revenue can have a bigger impact, and these companies might be positioned to take advantage of an otherwise tough situation.
Graham (NYSE:GHM) reported record fiscal 2026 revenue, orders and backlog, with management pointing to strong demand in defense, improving momentum in space and contributions from recent acquisitions as the company enters fiscal 2027.
On the company’s fiscal fourth-quarter earnings call, President
Assembly Biosciences (NASDAQ:ASMB) outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming decisions tied to its herpes simplex virus type 2 program, expansion of its hepatitis delta candidate
"Quality" stocks may be better able to withstand market turbulence thanks to stable earnings, strong balance sheets, and more; these ETFs aim to find them.
Optical Cable (NASDAQ:OCC) reported sharply higher fiscal second-quarter sales and profit, with management citing strength in enterprise, data center and severe-duty markets, as well as improved manufacturing leverage.
On the company’s fiscal 2026 second-quarter earnings call, President and Chief E
Marc Lichtenfeld highlights HAL, CVX, and HASI as energy stocks positioned to benefit from AI-driven electricity demand growth forecast at 3.5% annually through 2030.
Duluth (NASDAQ:DLTH) reported a narrower first-quarter loss and higher gross margins as management said its ongoing effort to reduce promotions, rationalize inventory and cut costs continued to reshape the apparel retailer’s financial profile.
President and Chief Executive Officer Stephanie Puglies
FuelCell Energy (NASDAQ:FCEL) reported a wider second-quarter loss for fiscal 2026 as a non-cash impairment tied to its Groton Navy project weighed on results, while management emphasized a sharply expanding sales pipeline tied largely to data center and artificial intelligence-related power demand.
Gamehaus (NASDAQ:GMHS) reported third-quarter fiscal 2026 revenue above its prior guidance range while management emphasized improving profitability, tighter marketing discipline and growing use of direct-to-consumer payments and artificial intelligence across the business.
On the company’s earning
VinFast Auto (NASDAQ:VFS) reported sharply higher first-quarter 2026 vehicle deliveries and revenue, while management said gross margin was pressured by accounting impacts tied to an expanded free-charging program and other adjustments.
On the company’s earnings call, Chairman Pham Nhat Quan Anh sa
Berkshire Hathaway just turned over a rock that many would not think to look under. See the status of its latest portfolio addition, retail giant Macy's.
Campbell's (NASDAQ:CPB) reported lower third-quarter fiscal 2026 results as weaker volumes, inflation and supply chain costs weighed on sales and profitability, while management reaffirmed its full-year outlook and said it is continuing to invest behind key brands.
President and CEO Mick Beekhuizen
Compass Therapeutics (NASDAQ:CMPX) Chief Executive Officer Tom Schuetz said the company is preparing for a key U.S. Food and Drug Administration meeting on tovecimig, its DLL4/VEGF bispecific antibody, after a randomized study in advanced biliary tract cancer met its primary endpoint and a key secon
AstroNova (NASDAQ:ALOT) reported higher fiscal first-quarter revenue and improved profitability, driven primarily by strength in its Aerospace segment, as management said the company is benefiting from commercial aircraft demand, growing orders and internal cost controls.
On the company’s fiscal 20
Basf (ETR:BAS) executives said the company’s new Zhanjiang Verbund site in Guangdong province has started operations successfully, positioning the German chemicals group for further growth in China while adding a major new production platform built around digitalization, feedstock flexibility and re
CME Group (NASDAQ:CME) Chairman and CEO Terry Duffy sharply criticized the Commodity Futures Trading Commission’s approval of a Bitcoin perpetual futures contract for Kalshi, saying the product does not fit his view of a futures contract and raises risks for retail investors.
Speaking at an investo
Chime Financial (NASDAQ:CHYM) founder and CEO Chris Britt outlined the digital banking company’s growth strategy, product roadmap and margin targets during a presentation at the William Blair conference, emphasizing Chime’s focus on primary checking relationships and mainstream U.S. consumers.
Brit
CG Oncology (NASDAQ:CGON) is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the Jefferies Global Healthcare Conference in New York.
Kuan said the company believes the therapy cou
Certara (NASDAQ:CERT) executives outlined the company’s strategic realignment, artificial intelligence initiatives and cost priorities during a discussion at Jefferies’ 2026 Global Healthcare Conference, with newly appointed Chief Executive Officer Jon Resnick saying the company is focused on creati
MetLife, Globe Life, and Unum Group are hitting 52-week highs as P&C premiums decline, rewarding insurers with life, group benefits, and health exposure.
Celsius (NASDAQ:CELH) executives said the company is working through a major portfolio transition as it integrates Alani and Rockstar into its platform while repositioning the core Celsius brand for renewed growth.
Speaking at an investor conference, Chairman and CEO John Fieldly described the comp
Market rotation into robotics, crypto infrastructure, AI data centers, and precious metals is creating opportunities in speculative stocks under $20, including SERV, BTBT, and CDE.
U.S. rig counts are climbing for the first time in years. Here are three energy stocks to buy on the dip — and two names analysts say to avoid right now.
CareDx (NASDAQ:CDNA) executives outlined the company’s growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing transplant diagnostics, specialty oncology and digital workflow integration.
John Hanna, chief executiv
Bruker (NASDAQ:BRKR) is seeing stronger order momentum across several end markets, with semiconductor metrology, non-U.S. academic and government customers, and parts of its diagnostics business helping offset continued weakness in U.S. academic funding, a company representative said at a Jefferies
Black Rock Coffee Bar (NASDAQ:BRCB) executives outlined the company’s growth strategy, store economics and competitive positioning during a William Blair consumer event, emphasizing plans to sustain rapid unit expansion while leaning on customer loyalty, store-level execution and a differentiated ca
Backblaze (NASDAQ:BLZE) Chief Executive Gleb Budman said the cloud storage company is seeing a material shift in demand tied to artificial intelligence workloads, as customers seek alternatives to hyperscaler platforms and newer AI-focused cloud providers look to add storage capabilities.
Speaking
Blackbaud (NASDAQ:BLKB) executives emphasized the company’s nonprofit software focus, artificial intelligence initiatives, payments opportunity and capital return strategy during a discussion hosted by Baird Senior Research Analyst Rob Oliver.
Oliver described Blackbaud as a vertical software leade
IREN Limited is pivoting from Bitcoin mining to AI infrastructure, securing an 800MW data center campus in Australia and a $3.65 billion Microsoft-backed financing facility.
BlackLine (NASDAQ:BL) executives said the company is leaning on platform pricing, artificial intelligence and deeper enterprise adoption as it works to reaccelerate revenue growth, according to remarks at a William Blair conference session.
Chair and CEO Owen Ryan described BlackLine as a “mission-
U.S. EV sales fell 27% in Q1 2026 after federal tax credits ended, creating diverging outlooks for Rivian, Lucid, and Tesla amid continued global EV growth.
BioAge Labs (NASDAQ:BIOA) executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company’s plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts expected in cardiovascular risk and diabetic macular edema.
The company’s chief business officer
Black Diamond Therapeutics (NASDAQ:BDTX) is positioning its lead oncology drug candidate, silevertinib, as a potential treatment for non-small cell lung cancer patients with non-classical EGFR mutations, Chief Executive Officer Mark Velleca said during a Jefferies fireside chat following the company
BioCryst Pharmaceuticals (NASDAQ:BCRX) CEO Charlie Gayer said the company remains on track with its commercial and development plans during a Jefferies fireside chat, highlighting continued growth expectations for hereditary angioedema drug ORLADEYO, progress for late-stage HAE candidate navenibart
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing to launch Auvelity in Alzheimer’s disease agitation this month while continuing to expand the drug’s use in major depressive disorder and advance a broad central nervous system pipeline.
Speaking at a Jefferies fireside chat
Axon Enterprise (NASDAQ:AXON) President Josh Isner said the company continues to see durable growth opportunities across public safety, international markets, enterprise customers and new artificial intelligence products, speaking during a William Blair & Company fireside chat hosted by research
Avalyn Pharma (NASDAQ:AVLN) executives outlined the company’s inhaled pulmonary fibrosis strategy at the Jefferies Global Healthcare Conference, emphasizing its recent IPO, ongoing mid-stage studies and plans to position its candidates as potential backbone therapies for idiopathic pulmonary fibrosi
AeroVironment (NASDAQ:AVAV) executives told investors at William Blair’s 46th Annual Growth Stock Conference that the company sees expanding opportunities across drones, loitering munitions and counter-drone systems, while also emphasizing ongoing capacity investments tied to programs such as Switch
Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications, Chief Executive Officer Jason Okazaki said during a Jefferies biotech event.
Okazaki said 2024 w
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer James Hamilton emphasizing that the company remains focused exclusively on siRNA therapeutics through
Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that m
Quanex Building Products (NYSE:NX) reported a modest increase in fiscal second-quarter revenue but sharply lower earnings, as inflation in raw materials, freight and logistics weighed on margins and led the company to withhold reaffirmation of its prior full-year outlook.
On the company’s earnings
Navitas Semiconductor solves severe thermal bottlenecks in artificial intelligence server racks by fundamentally transforming power delivery architecture.
StealthGas (NASDAQ:GASS) reported higher first-quarter revenue and continued to emphasize its debt-free balance sheet, growing cash position and charter coverage during its first-quarter 2026 earnings call.
Chairman Michael Jolliffe said revenue rose to $42.8 million in the quarter, up 2% from $42
